Related Experiment Video

Updated: Jun 14, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics

Philip E Tarr1, Margalida Rotger, Amalio Telenti

  • 1Infectious Disease Service, Infektiologie & Spitalhygiene, Kantonsspital Bruderholz, University of Basel, 4101 Bruderholz, Switzerland. philip.tarr@unibas.ch

Pharmacogenomics
|March 31, 2010
PubMed

Insights

Antiretroviral therapy and genetic factors both significantly impact dyslipidemia in HIV patients. Understanding these combined effects is crucial for managing cardiovascular disease risk in this population.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Infectious Diseases

Background:

  • HIV infection is linked to accelerated atherosclerosis and premature coronary artery disease.
  • Dyslipidemia is a primary driver of this increased cardiovascular risk.
  • Antiretroviral therapy (ART) is a known contributor to dyslipidemia in HIV-infected individuals.

Purpose of the Study:

  • To investigate the contribution of genetic factors, specifically single nucleotide polymorphisms (SNPs), to dyslipidemia in HIV-infected patients on ART.
  • To compare the impact of ART and genetic background on serum lipid variability.

Main Methods:

  • Leveraged findings from nine genome-wide association studies (GWAS) identifying SNPs associated with dyslipidemia.
  • Analyzed a Swiss HIV-infected study population to assess the interplay between ART and genetic variants.
  • Examined the contribution of common SNPs to lipid profiles, including high LDL cholesterol, low HDL cholesterol, and hypertriglyceridemia.

Main Results:

  • GWAS-validated SNPs were found to contribute to dyslipidemia in the context of HIV infection and ART.
  • In the study population, ART and genetic background explained similar proportions of serum lipid variability.
  • Both ART and the cumulative effect of SNPs contribute to adverse lipid profiles in individual patients.

Conclusions:

  • Genetic predisposition, alongside ART, plays a significant role in the development of dyslipidemia in HIV-infected individuals.
  • These genetic factors may also contribute to other metabolic complications like diabetes and coronary artery disease.
  • Future research focusing on rare SNPs and structural variants aims to further elucidate the heritability of complex metabolic traits in this population.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...